MD4624C1 - Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice - Google Patents

Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice

Info

Publication number
MD4624C1
MD4624C1 MD20160027A MD20160027A MD4624C1 MD 4624 C1 MD4624 C1 MD 4624C1 MD 20160027 A MD20160027 A MD 20160027A MD 20160027 A MD20160027 A MD 20160027A MD 4624 C1 MD4624 C1 MD 4624C1
Authority
MD
Moldova
Prior art keywords
oncolytic
immuno
vaccinia viruses
therapies
viruses
Prior art date
Application number
MD20160027A
Other languages
English (en)
Russian (ru)
Other versions
MD20160027A2 (ro
MD4624B1 (ro
Inventor
Stephen Howard Thorne
Original Assignee
Univ Pittsburgh Commonwealth Sys Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh Commonwealth Sys Higher Education filed Critical Univ Pittsburgh Commonwealth Sys Higher Education
Publication of MD20160027A2 publication Critical patent/MD20160027A2/ro
Publication of MD4624B1 publication Critical patent/MD4624B1/ro
Publication of MD4624C1 publication Critical patent/MD4624C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Invenţia se referă la virusuri oncolitice de vaccin variolic, modificate pentru a stimula imunitatea antitumorală şi/sau a diminua imunitatea gazdei şi/sau răspunsul anticorpilor gazdei împotriva virusului.Esenţa invenţiei constă în aceea, că virusul oncolitic de vaccin variolic conţine un acid nucleic, care codifică domeniul Toll/IL-1R cu conţinut de proteină adaptoare, care induce interferon beta (TRIF) sau un domeniu funcţional al acesteia. De asemenea invenţia se referă la metode de utilizare a virusurilor oncolitice în tratamentul tumorilor maligne.
MD20160027A 2013-08-22 2014-08-22 Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice MD4624C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361868978P 2013-08-22 2013-08-22
PCT/US2014/052308 WO2015027163A1 (en) 2013-08-22 2014-08-22 Immuno-oncolytic therapies

Publications (3)

Publication Number Publication Date
MD20160027A2 MD20160027A2 (ro) 2016-08-31
MD4624B1 MD4624B1 (ro) 2019-03-31
MD4624C1 true MD4624C1 (ro) 2019-10-31

Family

ID=52484194

Family Applications (2)

Application Number Title Priority Date Filing Date
MD20160027A MD4624C1 (ro) 2013-08-22 2014-08-22 Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice
MDA20180086A MD4748C1 (ro) 2013-08-22 2014-08-22 Terapii imunooncolitice

Family Applications After (1)

Application Number Title Priority Date Filing Date
MDA20180086A MD4748C1 (ro) 2013-08-22 2014-08-22 Terapii imunooncolitice

Country Status (26)

Country Link
US (2) US11478518B2 (ro)
EP (3) EP4324918A3 (ro)
JP (3) JP6912199B2 (ro)
KR (1) KR102389240B1 (ro)
CN (1) CN105658795B (ro)
AU (1) AU2014308648B2 (ro)
CA (3) CA2921041C (ro)
DK (2) DK3778897T3 (ro)
EA (1) EA037582B1 (ro)
ES (2) ES2847305T3 (ro)
FI (1) FI3778897T3 (ro)
HK (1) HK1223402A1 (ro)
HR (1) HRP20240078T1 (ro)
IL (1) IL243996A0 (ro)
LT (1) LT3778897T (ro)
MD (2) MD4624C1 (ro)
MX (1) MX2016002257A (ro)
NZ (1) NZ716825A (ro)
PE (1) PE20160673A1 (ro)
PH (1) PH12016500329A1 (ro)
PL (1) PL3778897T3 (ro)
PT (1) PT3778897T (ro)
RS (1) RS65104B1 (ro)
SG (1) SG11201600960PA (ro)
SI (1) SI3778897T1 (ro)
WO (1) WO2015027163A1 (ro)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3778897T (lt) 2013-08-22 2024-02-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Imunoonkolitinės terapijos
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
EP3327137B1 (en) * 2015-07-22 2020-12-09 National University Corporation Tottori University Host regulation factor for enhancing proliferation and propagation of vaccinia virus
US10646524B2 (en) 2015-09-08 2020-05-12 Sillajen, Inc. Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof
EP3371221A2 (en) 2015-11-07 2018-09-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN116440176A (zh) 2016-02-25 2023-07-18 纪念斯隆凯特琳癌症中心 具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
CN109152736A (zh) * 2016-03-25 2019-01-04 联邦高等教育系统匹兹堡大学 合成包封病毒
EP3254692A1 (en) * 2016-06-10 2017-12-13 Ceva Sante Animale Multivalent recombinant spv
KR102619496B1 (ko) * 2016-07-19 2023-12-29 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Stat3를 타겟으로 하는 종양용해성 바이러스
WO2018057755A1 (en) * 2016-09-21 2018-03-29 Thorne Stephen H High mobility group box i mutant
GB201616365D0 (en) 2016-09-27 2016-11-09 Helsingin Yliopisto Non-genetic modification of enveloped viruses
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
CA3052463A1 (en) * 2017-02-03 2018-08-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
EP3593136A1 (en) * 2017-03-06 2020-01-15 Talaris Therapeutics, Inc. Methods and compositions for determining the potency of a therapeutic cellular composition
ES2971065T3 (es) * 2017-04-21 2024-06-03 Sillajen Inc Terapia de combinación de virus vaccinia oncolítica y un inhibidor de punto de control
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
EP3703723A4 (en) * 2017-10-31 2021-12-15 KaliVir Immunotherapeutics, Inc. ONCOLYTIC PLATFORM VECTOR FOR SYSTEMS ADMINISTRATION
JP2021503965A (ja) 2017-12-01 2021-02-15 スッター，ゲルド 複製効率の高い免疫調節ワクシニアウイルス株
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
WO2020036635A2 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
CA3106983A1 (en) * 2018-07-20 2020-01-23 Ansun Biopharma, Inc. Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
PE20212307A1 (es) * 2018-12-21 2021-12-10 Ottawa Hospital Res Inst Vectores de orthopoxvirus modificados
CA3125020A1 (en) * 2019-01-07 2020-07-16 Kalivir Immunotherapeutics, Inc. Methods of treating cancer
TW202038994A (zh) * 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
EP3923967A1 (en) 2019-02-14 2021-12-22 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
EP4045657A4 (en) * 2019-10-16 2023-11-15 KaliVir Immunotherapeutics, Inc. MODIFIED EXTRACELLULAR ENVELOPED VIRUS
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
JP2021106576A (ja) * 2019-12-12 2021-07-29 イグナイト・イミュノセラピー，インコーポレーテッド 変異体腫瘍溶解性ワクシニアウイルスおよびその使用法
AU2021205287A1 (en) * 2020-01-09 2022-07-21 Pfizer Inc. Recombinant vaccinia virus
JP2024516400A (ja) * 2021-04-30 2024-04-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 修飾されたｍｈｃ発現のための腫瘍溶解性ウイルス
EP4363059A1 (en) * 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269618A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
WO2007023725A1 (ja) * 2005-08-25 2007-03-01 Yokohama City University 遺伝子ワクチン
AU2012244210B2 (en) * 2005-09-07 2014-10-02 Sillajen Biotherapeutics, Inc. Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) * 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
KR20090004839A (ko) * 2005-09-07 2009-01-12 제네렉스, 인코포레이티드 Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성및/또는 전신 파종성 암의 전신 치료법
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
US20110038843A1 (en) * 2008-03-31 2011-02-17 Kusmartsev Sergei A Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment
DK2477499T3 (en) 2009-09-14 2018-06-06 Sillajen Biotherapeutics Inc COMBINATION CANCER THERAPY WITH ONCOLYTIC VACCINIA VIRUS
US20130202639A1 (en) 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
EP2697368B1 (en) * 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
LT3778897T (lt) 2013-08-22 2024-02-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Imunoonkolitinės terapijos

Also Published As

Publication number Publication date
KR102389240B1 (ko) 2022-04-20
EP3036329B1 (en) 2020-10-07
MD4748C1 (ro) 2021-09-30
NZ716825A (en) 2022-02-25
PH12016500329A1 (en) 2016-05-02
MD4748B1 (ro) 2021-02-28
EP3036329A4 (en) 2017-08-02
JP2019205451A (ja) 2019-12-05
CA3213715A1 (en) 2015-02-26
EP3036329A1 (en) 2016-06-29
CA3213683A1 (en) 2015-02-26
PT3778897T (pt) 2024-02-01
SI3778897T1 (sl) 2024-03-29
FI3778897T3 (fi) 2024-01-25
HRP20240078T1 (hr) 2024-03-29
CN105658795B (zh) 2020-07-03
AU2014308648B2 (en) 2020-11-12
EA201690444A1 (ru) 2016-08-31
US11478518B2 (en) 2022-10-25
ES2847305T3 (es) 2021-08-02
EP3778897A1 (en) 2021-02-17
DK3778897T3 (da) 2024-01-29
EP3778897B1 (en) 2023-12-20
HK1223402A1 (zh) 2017-07-28
CA2921041C (en) 2023-10-31
JP7021154B2 (ja) 2022-02-16
ES2971528T3 (es) 2024-06-05
JP7333431B2 (ja) 2023-08-24
WO2015027163A9 (en) 2016-04-14
EP4324918A2 (en) 2024-02-21
DK3036329T3 (da) 2021-01-11
EP4324918A3 (en) 2024-04-24
CA2921041A1 (en) 2015-02-26
JP2022062171A (ja) 2022-04-19
WO2015027163A1 (en) 2015-02-26
CN105658795A (zh) 2016-06-08
LT3778897T (lt) 2024-02-12
EA037582B1 (ru) 2021-04-16
US20160235793A1 (en) 2016-08-18
MD20160027A2 (ro) 2016-08-31
MD20180086A2 (ro) 2019-03-31
PL3778897T3 (pl) 2024-04-02
KR20160044529A (ko) 2016-04-25
MD4624B1 (ro) 2019-03-31
IL243996A0 (en) 2016-04-21
SG11201600960PA (en) 2016-03-30
MX2016002257A (es) 2016-11-08
RS65104B1 (sr) 2024-02-29
JP6912199B2 (ja) 2021-08-04
US20230008089A1 (en) 2023-01-12
PE20160673A1 (es) 2016-07-21
AU2014308648A1 (en) 2016-03-03
JP2016527920A (ja) 2016-09-15

Similar Documents

Publication Publication Date Title
MD4624C1 (ro) Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
CY1123563T1 (el) Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων
MX2019004810A (es) Ácidos ribonucleicos mensajeros para aumentar respuestas inmunes y métodos para usarlos.
PH12018500858A1 (en) Nucleic acid vaccines for varicella zoster virus (vzv)
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
CL2019000392A1 (es) Métodos para detectar aav.
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
MD4655C1 (ro) Virusurile bolii de Newcastle şi utilizarea acestora
EA201891022A1 (ru) Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
WO2015109124A3 (en) Immunomodulatory agents
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
PH12016500388A1 (en) Gitr antigen binding proteins
BR112016000303A2 (pt) partícula tipo viral que compreende antígeno pd-1 ou antígeno ligante pd-1, molécula de ácido nucleico isolada, vetor, composição farmacêutica, uso dos mesmos, e kit
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX2019007921A (es) Nuevos agentes de union a ha.
BR112017023131A2 (pt) anticorpos anti- fcrn
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
EP3426272A4 (en) HSV-1 ONCOLYTIC VIRUS THERAPIES THAT TARGET ALT-DEPENDENT CANCERS
PH12018500203A1 (en) Anti-cd154 antibodies and methods of using them
EA201792058A1 (ru) Виротерапия комбинацией антител
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
PH12016501444A1 (en) Antibodies against f glycoprotein of hendra and nipah viruses
MX2017003694A (es) Sistema de genética inversa del virus pichindé y métodos de uso.

Legal Events

Date Code Title Description
FG4A Patent for invention issued